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Abstract: Infections are common complications in joint replacement surgeries. Eradicated infections
can lead to implant failure. In this paper, analogues of the peptide KR-12 derived from the human
cathelicidin LL-37 were designed, synthesised, and characterised. The designed antimicrobial
peptides (AMPs) were attached to the surface of a titanium alloy, Ti6Al4V, by conjugation to a
polydopamine linking substrate. The topography of the polydopamine coating was evaluated by
electron microscopy and coating thickness measurements were performed with ellipsometry and
Atomic Force Microscopy (AFM). The subsequently attached peptide stability was investigated with
release profile studies in simulated body fluid, using both fluorescence imaging and High-Performance
Liquid Chromatography (HPLC). Finally, the hydrophobicity of the coating was characterised by
water contact angle measurements. The designed AMPs were shown to provide long-term bonding
to the polydopamine-coated Ti6Al4V surfaces.
Keywords: Ti6Al4V; polydopamine; antimicrobial peptides; cathelicidin; KR-12
1. Introduction
Infection are the most common complications of joint replacement surgery, with nosocomial or
hospital-acquired infections ranking as the sixth leading cause of death, presenting a major healthcare
challenge [1]. Infection can lead to extended inflammation at the site of the surgery, thus causing the
rejection and failure of the implant [2]. Although the administration of antibiotics significantly reduces
the risk of postsurgical infections, bacterial biofilm production on the implant surface or untimely
administration of antibiotics will reduce their effectiveness [3].
The use of titanium in dental and orthopaedic implants is well established due to titanium’s
strength, stiffness, and corrosion resistance. Titanium also shows seamless integration with the
surrounding tissues due to its excellent biocompatibility [4,5]. The drawback of using titanium
implants is their susceptibility to bacterial colonisation on the surfaces of the implants [6]. To combat
the formation of biofilms on implant surfaces, the time-controlled release of various antibiotic coatings
has previously been investigated [7,8]. However, the release of the antibiotics below the level of
the minimum inhibitory concentration (MIC) is known to produce antibiotic-resistant strains of bacteria.
Higher levels of antibiotic release have been shown to be toxic to the surrounding tissues. The increase of
antibiotic-resistant bacteria has led to the search for an alternative method of antimicrobial protection [9].
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Antimicrobial peptides, which are a part of the innate immune system of all living organisms, have
broad-spectrum activity against many microorganisms, such as Gram-positive bacteria, Gram-negative
bacteria, viruses, and fungi [10–13]. Moreover, they can inhibit biofilm formation and induce
its dissolution, as well as attract phagocytes to further induce natural defence mechanisms [14].
The mechanisms of action of antimicrobial peptides (AMPs) against bacteria are not fully understood
due to the high diversity of these peptides. Nevertheless, it is widely accepted that bacterial cell death
is due to the interaction of cationic AMPs with negatively charged phospholipids on the bacterial
membrane, which lead to the loss of membrane structural integrity, and eventually cell death [10–13].
AMPs exhibit a strong preference for specific membrane compositions, allowing them to be selective
towards bacterial cell membranes, but not mammalian or plant cells [14]. Currently, only a few AMPs
are used clinically due to limiting factors, such as the high cost of peptide synthesis, their susceptibility
to proteolytic degradation, and their unknown long-term toxicology profiles [1,14,15]. Here, analogues
of the peptide KR-12 derived from the human cathelicidin LL-37 were designed due to its established
antimicrobial activity and lack of mammalian cell toxicity, as originally found by Jacob et al. [16].
To introduce the antimicrobial peptides stably on a surface, different types of coatings can be
employed. A popular approach is the use of polydopamine (pDA), a strong adhesive mussel-inspired
polymer, due to its low cost, simplicity of application, and improved biocompatibility [17–19].
Similarly to mussel adhesive proteins, the adhesive properties of the pDA are owed to quinine and
catechol groups, which create chelating structures with metals. Additionally, after polymerisation,
pDA can be further functionalised with amine-containing nucleophiles, such as proteins and peptides.
This allows the application of a pDA coating to Ti6Al4V, where the in-house designed analogues of the
peptide KR-12 are subsequently covalently bonded to the pDA coating.
2. Materials and Methods
2.1. Peptide Design
The shortest active peptide fragment derived from cathelicidin LL-37, KR12, was used as a
template to design three peptides of varying antimicrobial activity. The peptide sequences and various
properties are summarised in Table 1.
Table 1. Table showing the used peptides sequences, including their charge, hydrophobicity, and
amphiphacity, determined by hydrophobic characteristics. Within the sequences, positively charged
residues are marked in blue, the negatively charged in red, and highly hydrophobic sequences are
underlined.
Peptide Sequence Length ofSequence
Net
Charge
Charge
Density
Mean
Hydrophobicity
[H]
Helical
Hydrophobic
KR12 KRIVQRIKDFLR 12 aa +4 0.33 0.193 0.782
KR12/32 KIRVQRIKDFLR 12 aa +4 0.33 0.193 0.429
KR12-5911 KRIVRIKFR 9 aa +5 0.56 0.178 0.395
KR12/32-5911 KIRVRIKFR 9 aa +5 0.56 0.178 0.092
2.2. Peptide Synthesis, Purification
Peptides dyed with carboxyfluorescein (5(6)-FAM) were synthesised in-house following conventional
solid-phase peptide synthesis (SPPS). After synthesis, the peptides were purified to show a minimum purity
of >95%. Peptides without the dye exhibited a purity of >98% and were purchased from ProteoGenix,
Schiltigheim, France. All the amino acids used in SPPS (i.e., Fmoc–Ala–OH, Fmoc–Asp(OtBu)–OH,
Fmoc–Glu(OtBu)–OH, Fmoc–Phe–OH, Fmoc–Gly–OH, Fmoc–Ile–OH, Fmoc–Lys(Boc)–OH, Fmoc–Leu–OH,
Fmoc–Asn–OH, Fmoc–Gln–OH, Fmoc–Pro–OH, Fmoc–Arg(Pbf)–OH) were purchased from AGTC
Bioproducts Ltd., Itlings Lane Hessle, UK, with a purity of >98 % purity, which were side-chain protected
where appropriate. Preloaded Wang resin with Fmoc-protected amino acids (Fmoc–Arg(Pbf) Wang,
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Fmoc–Glu(OtBu) Wang, Fmoc–Lys(Boc)–OH) with peptide substitutions in the range of 0.21–5.3 mmol/g
and o-benzotriazole–N,N,N′,N′–tetramethyl–uronium–hexafluoro-phosphate (HBTU) of >98% purity
were purchased from NovaBiochem, Merck Life Science UK Limited, Watford, UK. Anhydrous N,N
dimethylformide (DMF), anhydrous dichloromethane (DCM), 5(6)-FAM, piperidine/DMF 20% mix (v/v),
ninhydrin, trifluoroacetic acid (TFA), and triisopropylsilane (TIPS) were all HPLC grade with >99% purity,
which were purchased from Sigma Aldrich, Merck Life Science UK Limited, Dorset, UK. Anhydrous diethyl
ether of HPLC grade used for precipitation of peptides was purchased from Fisher Scientific UK Ltd.,
Loughborough, UK. SPPS reactions were carried out in Aldrich® System 45™ vessels with caps and fritted
discs purchased from Sigma Aldrich, Merck Life Science UK Limited, Dorset, UK. Acetonitrile and TFA
used for peptide purification and for purity analysis with high-pressure liquid chromatography (HPLC)
were of HPLC grade and were purchased from Sigma Aldrich, Merck Life Science UK Limited, Dorset, UK.
Once ready for cleavage, the dried Wang resin beads were weighed and transferred from the
reaction vessel into a 50 mL round-bottom flask equipped with a magnetic stirrer. A fresh cleavage
mixture made of TFA, dH2O, and TIPS (v/v/v = 95/2.5/2.5) was then prepared and 10 mL per 0.1 g of
dried resin beads was added to the Wang resin beads in the round-bottom flask. The flask was then
carefully closed and wrapped with aluminium foil to prevent photo-bleaching. The reagents were
left to react under gentle and continuous stirring for 3–5 h. Subsequently, the Wang resin beads were
removed by vacuum filtration and the peptides were dissolved in the cleavage mixture. The peptides
were then precipitated by adding the solution dropwise to ice-cold diethyl ether. To ensure maximum
precipitation, the diethyl ether was kept overnight at −20 ◦C. The precipitate was then separated
from the supernatant by centrifugation at 13,500 rpm and air-drying overnight at −20 ◦C. The dried
crude peptide powder was dissolved in dH2O and then freeze-dried using a LyoDry Midi freeze dryer
(MechaTech Systems Ltd., Bristol, UK).
Labelling of the synthesised peptides with the fluorescence dye 5(6)-FAM was performed while
the molecules were still attached to the Wang resin. The reaction is similar to the amino acid coupling.
A mixture of 5 equiv 5(6)-FAM and 4.9 equiv HBTU dissolved in DMF (≈3 mL) was placed in a reaction
vessel containing a known amount of washed Wang resin with a previously deprotected N-terminal
peptide sequence. The reaction vessel was wrapped with aluminium foil to prevent photo-bleaching
and was placed on an orbital shaker. The reaction mixture was left to react overnight under continuous
shaking (≈200 rpm). It was then washed three times with DMF (6 mL) and three times with DCM
(6 mL). After the washing procedure, the resin beads were dried under vacuum until all of the DCM
was removed.
2.3. Peptide Characterisation
2.3.1. High-Pressure Liquid Chromatography
All peptides were purified with preparative HPLC using a Thermo Scientific Dionex Summit
preparative HPLC system (Thermo Fisher Scientific Ltd., Loughborough, UK). Their purity was tested
with a Thermo Scientific Dionex Summit analytical HPLC system. Both systems were equipped with
C18 columns, water with 0.05% TFA was used as the hydrophilic medium, and acetonitrile with 0.05%
TFA was used as the hydrophobic medium. The detection of molecules was conducted by measuring
the UV absorbance of the amide bond at a wavelength of 210 nm. For preparative HPLC, a total of
2 mL of crude peptide dissolved in a mixture of acetonitrile and water (v/v = 1) was injected into the
C18 column, while for analytical HPLC 100 µL of a similar peptide solution was added to the C18
column. In both cases, the columns were run for 60 min with a linear gradient of solvents starting at
100% dH2O and 0% acetonitrile, finishing at 0% water and 100% acetonitrile.
2.3.2. Mass Spectrometry
After purification, acetonitrile was evaporated with the use of a rotary evaporator and the peptides
were recovered by freeze-drying. Subsequently, the peptides were analysed on a Waters Micromass
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LCT TOF spectrometer (Waters UK, Wilmslow, UK) using electrospray ionisation in the School of
Chemistry Mass Spectrometry facility. Prior to mass analysis, the peptide samples were dissolved in
water. After the purification of the crude peptides, a purity of ≥95% was achieved and the theoretical
mass agreed with the calculated mass displayed in Table 2.
Table 2. Purity and mass analysis of peptides.
Peptide Theoretical MolecularWeight (g/mol)
Molecular Weight M
Measured by MS (g/mol)
Purity Calculated
by HPLC (%)
KR12 1572
M = 1574
[M + 2H]2+ = 788
[M + Na + H]2+ = 799
95
5(6)-FAM-labelled KR12 1904 M = 1903[M + 2H]2+ = 952 95
KR12/32 1572
M = 1572
[M + 2H]2+ = 787
[M + 3H]3+ = 525
99
5(6)-FAM-labelled
KR12/32 1904
M = 1903
[M + H]+ = 1904
[M + 2H]2+ = 952
95
KR12-5911 1216 M = 1215[M + 2H]2+ = 609 97
5(6)-FAM-labelled
KR12-5911 1548
M = 1547
[M + H]+ = 1549
[M + 2H]2+ = 775
95
KR12/32-5911 1216 M = 1215[M + 2H]2+ = 609 98
5(6)-FAM-labelled
KR12/32-5911 1548
M = 1547
[M + 2H]2+ = 775 96
KR12 1572
M = 1574
[M + 2H]2+ = 788
[M + Na + H]2+ = 799
95
5(6)-FAM-labelled KR12 1904 M = 1903[M + 2H]2+ = 952 95
2.3.3. Minimum Inhibitory Concentration (MIC) Values of Peptides
The minimum inhibition concentration (MIC) is used to determine the lowest concentration
of antimicrobial agent needed to inhibit the visible growth of a bacteria strain after overnight
incubation. All the bacteria strains were kindly provided by Dr Mark Webber of the Quadram Institute
Bioscience (Norwich, UK; Escherichia coli (E. coli, I364), Pseudomonas aeruginosa (P. aeruginosa, PAO1) and
Staphylococcus aureus (S. aureus, F77/NCTC8532)). Lysogen broth (LB broth) and agar were purchased
from Sigma-Aldrich, Merck Life Science UK Limited, Dorset, UK. Fresh LB agar culture plates were
prepared by pouring ≈10 mL of an autoclaved warm mixture of LB broth (2.5%) and bacteriological
agar (1.5%) dissolved in dH2O. The agar plate was streaked and incubated overnight at 36 ◦C. A single
bacterial colony was chosen and grown in 5 mL broth overnight under agitation at 36 ◦C. Subsequently,
50 µL of LB broth was added to wells 2–12 of a 96-well culture plate. AMPs were diluted to a
concentration of 256 µg/mL, added to well 1, and diluted two-fold down to column 11. Column 12 was
left empty, with no AMPs added. Then, 50 µL of the diluted overnight bacteria culture was added to
the wells and incubated at 36 ◦C for 18 h to allow bacteria to grow. After incubation, the well plates
were examined for bacterial growth and the lowest concentration of AMPs where clear liquid was
observed was assumed to be the minimum inhibitory concentration. Three measurements for each
peptide and against each type of bacteria were performed and the average values were obtained.
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2.4. Sample Preparation
Titanium alloy grade 5 (Ti6Al4V) plates with dimensions of 15 cm × 15 cm and a thickness of
0.1 cm were purchased from William Gregor Ltd., London, UK, and cut into 1 cm × 1 cm plates. Then,
the plates were mounted in conducting Bakelite and polished to mirror finish. Three steps were used
during polishing of the plates. First, Bakelite-mounted Ti6Al4V plates were ground with MD-Piano of
220 grit, with water used as a lubricant. Then, a DiaDuo-2 diamond of 9 µm grain size suspended in
water and an MD-Largo polishing plate were used. Finally, a colloidal suspension (OP-S) activated
with ammonia solution was used and polished on MD-Chem polishing disc. All the polishing materials
and equipment were purchased from Struers Ltd., Rotherham, UK. After polishing the plates to a
mirror finish, the highly polished surfaces were secured with electrical tape to prevent the introduction
of scratches and Bakelite was broken down to release the mounted Ti6Al4V plates. The tape was then
removed from the plates and any impurities introduced on the Ti6Al4V surfaces during the previous
steps were removed by cleaning the plates in an ultrasonic bath with water (15 min) and acetone
(15 min). The plates were dried overnight in a desiccator and were used within 48 h after cleaning.
Having been cleaned and polished to a mirror finish, Ti6Al4V plates were placed inside a 24-well
cell culture plate with the polished side facing upwards. Dopamine, purchased from Sigma-Aldrich,
was dissolved to a final concentration of 5 mg/mL in 50 mM Tris buffer (Fisher Scientific UK Ltd.,
Loughborough, UK) at pH = 8.5. Then, 1.5 mL of dopamine solution was transferred into the cell
culture plates containing the Ti6Al4V plates. Subsequently, the prepared plates were placed in the dark
for 24 h without a cover to allow simultaneous dopamine polymerisation in air and metallic surface
coating. Ti6Al4V plates coated with polydopamine (pDA) were washed to remove any loose pDA
particles and placed in a new set of 24-well cell culture plates. The AMP solution was then prepared by
dissolving peptides in a concentration equal to the MIC value for each peptide in 50 mM Tris buffer at
pH 7.4. Then, 1.5 mL of this solution was transferred into the cell culture plates with the pDA-coated
Ti6Al4V plates. The cell culture plates were then kept in the dark without a cover for 24 h to allow
conjugation of the peptides with the pDA. Finally, the plates were washed several times with dH2O to
remove unconjugated peptides. The prepared plates were stored in the dark in a desiccator to dry and
used within 7 days of preparation.
2.5. Topography of Coating
The topography analysis of the pDA- and AMP-conjugated pDA coatings was performed
with a Bruker Icon Atomic Force Microscope (Bruker UK Ltd., Coventry, UK). A silicone probe
was passed over the surface of the coatings and its displacement was recorded. This generated a
three-dimensional plot of the surface topography. In this research, images were recorded in static
mode over a 20 µm × 20 µm area. Ellipsometry was performed on a Jobin-Yvon UVISEL ellipsometer
(HORIBA UK Ltd., Northampton, UK) with a xenon light source. First, the light reflection of the
uncoated surface of the sample was measured to set the measurement baseline, then the height of the
coated surface was measured relative to the baseline.
2.6. Fluorescence Microscopy
Fluorescence microscopy was used to determine the conjugation of AMPs to the pDA with a
Leica DM6000B widefield epifluorescence microscope (Leica Microsystems Ltd., Milton Keynes, UK),
equipped with a 100 W short-arc epifluorescence mercury burner and a Leica DFL350 FX firewire
camera (Leica Microsystems Ltd., Milton Keynes, UK) located at the Institute of Biomedical Research
(IBR) in the School of Medicine, University of Birmingham. Measurements were performed with an
epifluorescence filter set at an excitation wavelength of 480 nm and a green emission wavelength of
527 nm, corresponding to the green fluorescence associated with 5(6)-FAM. For each sample, a set of
five random points were recorded for comparison and the brightness of the green light was analysed
using the ImageJ 1.46r analysis program.
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2.7. Scanning Electron Microscopy
Imaging of the uncoated and pDA-coated surfaces was performed on a Zeiss Supra 55VP scanning
electron microscope (Carl Zeiss Ltd., Zeiss House, Cambridge, UK). All measurements were conducted
on samples coated with ≈1 nm of the electrodeposited carbon film. A 10 kV electron beam and various
magnifications were used.
2.8. Coating Stability
In order to prepare the simulated body fluid (SBF), sodium chloride (NaCl), sodium bicarbonate
(NaHCO3), potassium chloride (KCl), potassium phosphate dibasic trihydrate (K2HPO4·3H2O),
magnesium chloride hexahydrate (MgCl2·6H2O), hydrochloric acid (HCl) 32%, calcium chloride
(CaCl2), sodium sulfate (Na2SO4), and tris(hydroxymethyl)aminomethane (Tris, (CH2OH)3CNH2)
were purchased from Sigma Aldrich, Merck Life Science UK Limited, Dorset, UK. The SBF was prepared
as described by Kokubo and Takadama [20]. The stability of the AMPs on the surface of Ti6Al4V
was performed in SBF by submerging and keeping AMP-coated plates in SBF at 37 ◦C for a total of
30 days. Analysis of the released AMPs to the solution was performed using two methodologies.
Firstly, the change in green light intensity of the pDA Ti6Al4V surfaces coated with 5(6)-FAM-labelled
peptides was analysed after 1 and 6 h, then at 1, 3, 7, 14, and 30 days of submersion in SBF, imaged
under fluorescence microscopy. Secondly, plates with no labelled peptides were immersed in SBF
solution and analysed by HPLC at the same time intervals. However, in this method, 100 µL of the SBF
solution was withdrawn to determine the cumulative absorbance at the same retention time for every
individual peptide.
2.9. Dynamic Contact Angle Analysis
Hydrophobicity was determined by a dynamic contact angle technique on a Dyne Technology
ThetaLite optical tensiometer (Dyne Testing Ltd., Lichfield, UK) located in the Science City Lab at the
School of Chemical Engineering, University of Birmingham. Deionised water was used as a liquid
medium to perform the contact angle measurements. The measurements were performed by recording
the contact and retraction angles of a 5 µL droplet released on and removed from the studied surface.
The recording time of each incident was set to 20 s and the camera recorded 10 frames/s. The droplets
were released and then removed at a speed of 5 mL/min. All surfaces were kept in a desiccator prior to
measurements and were each measured three times.
2.10. Cell Culture Studies
Human osteosarcoma cells (HOS) were purchased from the European Collection of Authenticated
Cell Cultures (catalogue number 87070202). Cultured cells were grown in RPMI medium supplemented
with 10% v/v fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM glutamine as a
monolayer in T75 cell culture flasks in a humidified atmosphere (5% CO2 incubator; 95% air) at 37 ◦C.
Cells were sub-cultured at approximately 80% confluency twice-weekly using a standard trypsin-EDTA
protocol. All cell cultures were confirmed as being free from Mycoplasma sp. contamination using the
EZ-PCR mycoplasma detection kit according to the manufacturer’s instructions (Biological Industries
USA, Cromwell, CT, USA). All cells were cultured up to passage 20 before being discarded. Before
cell culture, coated surfaces were placed flat with the coated surface facing upwards into a 6-well cell
culture dish. Surfaces were sterilised with 2 mL of 70% v/v ethanol for 30 min. Subsequently, surfaces
were washed with sterile phosphate-buffered saline (PBS, 3 × 2 mL). HOS cells (100,000) were added
and left to attach for 4 h. The medium was changed and cells were incubated for 5 and 7 days before
being prepared for analysis by electron microscopy.
Materials 2020, 13, 3714 7 of 19
3. Results
3.1. Antimicrobial Characterisation
The MIC values of the peptides KR12, KR12/32, KR12-5911, and KR12/32-5911 against E. coli,
P. aeruginosa, and S. aureus are shown in Figure 1 and compared against LL-37 in Table 3. The most
effective peptide against E. coli was peptide KR12-5911 at 0.5 µM, followed by KR12 at 2 µM, and
KR12/32 and KR12/32-5911 at 4 µM. The lowest MIC values against P. aeruginosa were observed for
peptides KR12 and KR12-5911 at 2 µM, whilst peptides KR12/32 and KR12/32-5911 showed MIC values
of 4 µM. For S. aureus, the most effective was peptide KR12/32-5911 with an MIC of 2 µM, followed by
KR12-5911 and KR12 at 8 µM and KR12/32 at 32 µM. All peptides show similar MIC values against
Gram-negative bacteria. Additionally, the peptides were more effective against Gram-negative bacteria
when compared to the Gram-positive bacteria, apart from KR12/32-5911.
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Figure 1. Minimum inhibitory concentration (MIC) values for the designed KR12 analogues.
Table 3. MIC values for the designed KR12 analogues compared to the LL-37 human cathelicidin.
Sequence
MIC Values (µM)
E. coli (I364) P. aeruginosa (PAO1) S. aureus (F77) eo etric ean
KR12 2 2 8 4.0
KR12/32 4 4 32 13.33
KR12-5911 0.5 2 8 3.5
KR12/32-5911 4 4 2 3.33
LL-37 [14] 8 8 4 6.67
3.2. Polymerisation of Dopamine
Dissolution of dopamine in the Tris buffer resulted in an immediate colour shift to light brown.
As the polymerisation proceeded, the colour became darker until the solution was black, as shown in
Figure 2. As can be observed, once the polymerisation took place for 96 h, a film formed between the
surface of the liquid and the air, resulting in a different reflection of light. Scanning electron microscopy
(SEM) micrographs of the pDA coatings a e shown in Figure 3. Figure 3a shows a clear boundary
between the uncoated and uniformly coated Ti6Al4V surfaces, wh le Figure 3b shows the bead-like
structure of the polydopamine (pDA) coating. The beads display a circular hape with an average
diameter of 86 ± 20 nm. It can be observed that the beads are in fact constructed of clusters of even
smaller particles with an average diameter of 10 ± 1 nm. Even though the clusters are densely packed,
there are visible inequalities in the shapes of the grooves in between the clusters.
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The thickness of the pDA coating was measured by both ellipsometry and AFM, the results of
which are shown in Table 4. The results for the thickness of the coating measured by both ellipsometry
and AFM agreed with one another. A 24-h immersion of Ti6Al4V plates in the dopamine solution
resulted in the growth of an approximately 10-nm-thick layer. The thickness of the coating steadily
increased to reach around 55 nm after 72 h, after which the growth plateaued.
Table 4. Polydopamine coating thickness as measured by ellipsometry and Atomic Force M.icroscopy (AFM).
Time of Immersion 24 h 48 h 72 h 96 h
Coating thickness measured by ellipsometry (nm) 10.2 ± 1.1 32.8 ± 1.1 52.4 ± 7.0 54.7 ± 6.4
Coating thickness measured by AFM (nm) 10.3 ± 0.5 34.1 ± 2.0 55.4 ± 9.0 57.1 ± 6.8
3.3. Fluorescence Microscopy
Fluorescence microscopy images of the various coated Ti6Al4V surfaces are shown in Figure 4a–f,
while the subsequent fluorescence intensities are shown below in Table 5. From the fluorescence
intensities of the peptide coating without the polydopamine, it can be observed that the peptide KR12
(Figure 4a) was present on the surface in the smallest quantities, while the lines presented in the
image originated from the surface roughness and defects of the unpolished Ti6Al4V surface prior to
coating. For the Ti6Al4V surfaces with a pDA linking substrate (Figure 4b–e), the green colour of
the carboxyfluorescein (5(6)-FAM)-labelled peptides was generally distributed uniformly across the
surface of Ti6Al4V, indicating a uniform peptide coating.
Materials 2020, 13, x FOR PEER REVIEW 9 of 19 
 
(b) 
Figure 3. SEM micrographs showing (a) the Ti6Al4V surface with a olydopamine (pDA) coating 
(l ft) and unc ated (right) at a magnification of 1000×, as w ll as (b) the pDA coating at 100,000× 
magnification. 
  a ine coating thicknes  as measured by ellipsometry and Atomic For e M.icroscopy 
(AFM). 
Time of Immersion 24 h 48 h 72 h 96 h 
Coating thickness measured by ellipsometry (nm) 10.2 ± 1.1 32.8 ± 1.1 2.4 ± 7.0 54.7 ± 6.4 
Coating thickness measured by AFM (nm) 10.3 ± 0.5 34.1 ± 2.0 55.4 ± 9.0 57.1 ± 6.8 
3.3. Fluorescence Microscopy 
Fluorescence microscopy images of the various coated Ti6Al4V surfaces are shown in Figure 4a–
f, while the subsequent fluorescence intensities are shown below in Table 5. From the fluorescence 
intensities of the peptide coating without the polydopamine, it can be observed that the peptide KR12 
(Figure 4a) was present on the surface in the smallest quantities, while the lines presented in the 
image originated from the surface roughness and defects of the unpolished Ti6Al4V surface prior to 
coating. For the Ti6Al4V surfaces with a pDA linking substrate (Figure 4b–e), the green colour of the 
carboxyfluorescein (5(6)-FAM)-labelled peptides was generally distributed uniformly across the 
surface of Ti6Al4V, indicating a uniform peptide coating.  
  
(a) (b) 
  
(c) (d) 
Figure 4. Cont.
Materials 2020, 13, 3714 10 of 19
Materials 2020, 13, x FOR PEER REVIEW 10 of 19 
 
  
(e) (f) 
Figure 4. Fluorescence microscopy images of the Ti6Al4V surface coated for 24 hours with 5(6)-FAM-
labelled (a) KR12, (b) pDA-KR12, (c) pDA-KR12/32, (d) pDA-KR12-5911, and (e) pDA-KR12/32-5911; 
and (f) for Ti6Al4V without coating. 
Table 5. Fluorescent intensity values of various Ti6Al4V peptide-coated surfaces over 24 h. 
 
5(6)-
FAM-
KR12 
pDA-5(6)-
FAM-KR12 
pDA-5(6)-
FAM-KR12/32 
pDA-5(6)-
FAM-KR12 
-5911 
pDA-5(6)-
FAM-KR12/32 
-5911 
Fluorescence 
intensity (FI) 
868 ± 144 1204 ± 37 1198 ± 44 1227 ± 42 1189 ± 52 
3.4. Peptide Release Studies 
The peptide release profiles were all studied in simulated body fluid (SBF) over a total period of 
30 days. The fluorescence-based release profiles of the pDA-attached peptides on the Ti6Al4V surface 
are shown in Figure 5. Roughly 30% of the peptides were released from the surface in the initial 6 
hours and 40–50% was released after 30 days. To verify the release profiles based on fluorescence, the 
studies were repeated with no labelled peptides and analysed by HPLC. The release profiles based 
on cumulative absorbance measured by HPLC are shown in Figure 6, which indicated that roughly 
70% of the cumulative peptides were released in the first 6 h.  
 
Figure 5. Release profile of 5(6)-FAM-labelled peptides that were released from the Ti6Al4V-coated 
surface based on fluorescence measurements; x-axis displayed in logarithmic scale (base = 12). 
Figure 4. Fluorescence i f the Ti6Al4V surface coated for 24 h with 5(6)-FAM-labelled
(a) KR12, (b) pDA-KR12, (c) pDA-KR12/32, (d) pDA-KR12-5911, and (e) pDA-KR12/32-5911; and (f) for
Ti6Al4V without coating.
Table 5. Fluorescent intensity values of various Ti6Al4V peptide-coated surfaces over 24 h.
5(6)-FAM-
KR12
pDA-5(6)-
FAM-KR12
pDA-5(6)-
FAM- KR12/32
pDA-5(6)-
FAM-KR12-5911
pDA-5(6)
-FAM-KR12/
32-5911
Fluorescence
intensity (FI) 868 ± 144 1204 ± 37 1198 ± 44 1227 ± 42 1189 ± 52
3.4. Peptide Release Studies
The peptide release profiles were all studied in simulated body fluid (SBF) over a total period
of 30 days. The fluorescence-based release profiles of the pDA-attached peptides on the Ti6Al4V
surface are shown in Figure 5. Roughly 30% of the peptides were released from the surface in the
initial 6 h and 40–50% was released after 30 days. To verify the release profiles based on fluorescence,
the studies were repeated with no labelled peptides and analysed by HPLC. The release profiles based
on cumulative absorbance measured by HPLC are shown in Figure 6, which indicated that roughly
70% of the cumulative peptides were released in the first 6 h.
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3.5. Wettability of the Surface
The changes of the water droplet contact angles on the uncoated and coated Ti6Al4V with pDA
and conjugated with KR12, KR12/32, KR12-5911, and KR12/32-5911 are shown in Figure 7. Three
main events can be observed in the graphs: expansion of the droplet’s volume from 1 µL to 6 µL,
the droplet’s volume of 6 µL remaining steady, and shrinkage of droplet’s volume from 6 µL to 1 µL.
The application of the pDA and conjugation of the peptides all decreased the water contact angle of the
surface of the Ti6Al4V, as shown in Table 6. Peptides KR12 and KR12/32 showed similar decreases in
contact angles of roughly 1.3◦ and 7.8◦ when compared to pDA and Ti6Al4V, respectively. The coating
containing peptide KR12/32-5911 had a contact angle about 1.0◦ smaller than those with peptides KR12
and KR12/32. However, the surface coated with the peptide KR12/32-5911 showed the biggest contact
angle changes of roughly 2.7◦ and 9.7◦ when compared to the Ti6Al4V sample with pDA coating and
the uncoated Ti6Al4V sample that was polished to mirror finish, respectively.
Table 6. Overview of the water contact angles during the steady droplet volume.
Surface Contact Angle at Steady Volume of the Droplet
Mirror polished Ti6Al4V 65.4◦ ± 1.6
Ti6Al4V coated with pDA 59.0◦ ± 1.2
Ti6Al4V coated with pDA and peptide KR12 57.7◦ ± 0.9
Ti6Al4V coated with pDA and peptide KR12/32 57.5◦ ± 0.7
Ti6Al4V coated with pDA and peptide KR12-5911 55.6◦ ± 1.1
Ti6Al4V coated with pDA and peptide KR12/32-5911 56.3◦ ± 0.5
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Figure 7. Changes of the water contact angles of the Ti6Al4V surface coated with (a) pDA, (b) pDA-KR12,
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3.6. Cell Studies
The micrographs presented in Figure 8a–l show the attachment of human osteosarcoma cells
(HOS) on the coated and uncoated Ti6Al4V surfaces taken at days 5 and 7 of incubation. HOS showed
consistent growth on all of the surfaces, except for the Ti/pDA surface decorated with the peptide
KR12/32-5911 shown in Figure 8k–l, where cells were observed to be detached on day 7 of culture.
On the Ti/pDA KR12/32 sample shown Figure 8g– , the surface cells showed a flatter morp ology
compared to the other surfaces. On all of the other surfaces, althou h min r differences in the densities
of cells ca be seen, th re is little change between the growth of cells and there is clear evidence of an
increase in the number of cells from day 5 to day 7 of culture.
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4. Discussion
4.1. Peptide MIC Characterisation
Infectio s aused by the investigated bacteria a e some f the most comm nly occurring i cidences
during orthopaedic joint replacement surgeries [21]. Factors such as prolonged antibiotic treatment
or administration below the MIC value have been shown to increase bacterial resistance towards
antibiotics [22]. Thus, it is important to design antimicrobial peptides with low MIC values that are
effective against orthopaedic bacteria. When comparing the MIC values of the human cathelicidin
LL-37 with the designed peptides, as summarised in Table 3, the KR12 peptide showed promising MIC
values with a higher antimicrobial tendency towards Gram-negative bacteria.
LL-37 was shown to have antimicrobial activity against fungi [23], bacteria [24], and viruses [23,25].
Additionally, it has immunostimulatory and immunomodulatory functions against infections [26] and
stimulates angiogenesis [27] during the wound healing process [28]. LL-37 immobilised on polymer
surfaces has also been proven to retain its antimicrobial activity [29]. Therefore, the designed KR12
analogous peptide may share similar properties with LL-37, but this remains to be investigated.
4.2. Polydopamine Coating of Ti6Al4V
Dissolving dopamine in a solution of alkaline pH changes the colour of the solution from
translucent white to brown, then eventually to black, as shown in Figure 2. This colour change can be
explained by the structure of dopamine. Dopamine contains phenol groups, and when polymerised
it creates polyphenols structures that contain many aromatic rings joined together [30]. Multiple
aromatic rings in close proximity in one molecule are known as charge transfer complexes, whereby
the charge is delocalised between the rings [31]. These complexes promote absorption of visible light,
causing electron transition from a lower electron state to higher electron state, as a result of which
a dark colour is observed [32]. Immersing Ti6Al4V plates in a solution of dopamine resulted in the
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formation of a thin film on the surface of the metallic plate, which agrees with Messersmith et al. [33],
who reported that pDA was able to adhere to virtually any surface and that its polymerisation in
slightly basic solution resulted in a film formation on the surface. The SEM morphology and topology
studies showed that the surface of the pDA coating was built from small round particles of ≈100 nm
diameter. It was proposed by Jiang et al. that the pDA first polymerises in nanoaggregates, which over
time attach themselves on the surface, creating a uniform coating [34,35].
The attachment of the nanoaggregates to the surface could potentially have been driven by the
sedimentation of the particles towards the bottom of the container where the substrate to be coated
was located. The coating then accumulated with more beads and increased the thickness of the coating,
which varied depending on the size of the beads accumulated. This could explain the ≈10 nm coating
thickness after the initial 24 h, and the increases of the thickness to 32 nm after 48 h and to 57 nm
after 52 h of pDA polymerisation. Similar film thickness growth was reported by Jiang et al. [33,35].
In this study, a thickness plateau was reached after 72 h of polymerisation. This pattern of growth was
also previously reported by Bensmann et al. [36], where the pDA film reached 62.8 nm in thickness
after 72 h and did not increase in thickness afterwards. Formation of the plateau can be explained by
the lack of oxygen after the formation of the first pDA layer. Since oxidation is a common reaction
of polyphenols [37], it can be assumed that the polymerisation required oxygen to continue and the
presence of the film limited the accessibility to oxygen. In addition, as oxidation on the surface will
continue as oxygen is available on the surface, polymerisation will eventually stop when dopamine
is consumed.
4.3. Peptide Attachment to Polydopamine
The KR12 analogous peptide labelled with 5(6)-FAM at the N-terminal was conjugated to an
already pDA-coated Ti6Al4V surface. The presence of the peptides was confirmed by the emitted
fluorescence, showing only small variations in the measured fluorescence intensities between the
different peptides. The quinone group of pDA is known to undergo a Schiff base reaction or Michael
addition without the use of any other reagent or catalyst, allowing the conjugation of biomolecules to
pDA [38]. The catechol group of the pDA is known to oxidise to quinone at a pH above 7.5 in excess
of oxygen, which is necessary for successful conjugation to nucleophiles [39]. Here, the designed
peptides contained two lysine residues that should be able to conjugate to pDA, but the first lysine was
presumed to be shielded by the bulky 5(6)-FAM label at the N-terminus. Therefore, it was expected
that pDA was conjugated with the second lysine residue relative to the N-terminus. It was observed
that the initial burst of peptides released approximately 25–35% of the peptides from the surface after
6 h, and approximately 40–50% was released after 30 days. The fluorescence release profile studies in
SBF indicated that 50–60% of the peptides potentially remained conjugated to the pDA after 30 days.
The initial burst of peptide release could be attributed to the release of unattached peptides to the
pDA that were not successfully removed during the wash step. After the initial burst, the rate of
release of the peptides decreased and was only reduced further by roughly 5–10% after the final
30 days. The release profile from the fluorescence was confirmed by HPLC using non-fluorescent
peptides. An initial ≈70% burst of cumulative peptide was released in the first 6 h, and a slower
subsequent release for the remaining period was observed. These release studies clearly showed that
these peptides were conjugated to the pDA-coated Ti6Al4V surface in a very stable manner through
the lysine residues.
4.4. Wettability of the Surface
New implants within the body come into immediate contact with extracellular fluid and moieties,
such as proteins, which are some of the first molecules to interact with the surfaces of an implant [40,41].
The optimal water contact angle of a biomaterial reported for bone-forming cells to attach to a surface
was reported to be 55◦ [42]. Metallic surfaces are very hydrophobic, resulting in slow integration
rates of the implant with the body. A water contact angle study of pDA-coated titanium surfaces
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by Nijhuis et al. reported that coated Ti6Al4V surfaces were much less hydrophobic (≈47◦) than the
uncoated surfaces (≈75◦) [43], presumably resulting in an improvement of the implant integration [44].
In this paper, we report that the introduction of pDA coating on the surface of Ti6Al4V resulted in
a decrease in the water contact angle from 65.4◦ ± 1.6 to 59.0◦ ± 1.2. The experimental values are in
agreement with prior research performed by Luo et al. [45], who reported on the water contact angle of
a pDA-coated Ti6Al4V surface. The water contact angle was further reduced to approximately 56.8◦
when the pDA coating was decorated with the peptides—the results varied depending on the used
peptide, but they all showed a reduction relative to the pDA-coated Ti6Al4V surface.
4.5. Cell Culture Studies
All surfaces showed attachment of cells on day 5, with no evidence of toxicity (which is determined
by any change of cell morphology or density compared to the plain titanium surface), with one exception
for the KR12/32-5911 surface. The cell morphology was generally "flattened" and fibroblast-like, typical
of the described HOS morphology in the literature [46]. The density of attached cells increased over
time, confirming that cells were viable and able to proliferate. In contrast, there was evidence that the
surface of KR12/32-5911 was toxic to the cells, and at day 7 there were no longer any cells.
5. Conclusions
In the present research, KR12 and three new analogous peptides were successfully synthesised and
showed promising antimicrobial activity against E. coli, P. aeruginosa, and S. aureus, with MIC values
generally being lower than that of their native peptide, the human cathelicidin LL-37. The titanium
surfaces were coated with pDA and characterised. Subsequently, the pDA-coated surfaces were
decorated with KR12 and the other three designed analogous peptides. The pDA coating provided a
long-term linking substrate for the peptides, which was confirmed by fluorescence microscopy and
HPLC. Cultured HOS cells showed good attachment and cell growth on the material surfaces, with no
visible toxicity towards the cells, except for the KR12/32-5911 peptide. This surface treatment shows
potential to provide long-term antimicrobial activity on many metallic and organic material surfaces
and could be used in biomedical materials and implants.
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